NCT03164694 2024-12-10
APPEAL
Sun Yat-sen University
Phase 2 Withdrawn
Clinical Trials
9 trialsNCT04490421 2021-02-08
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Fuzhou General Hospital
Phase 3 Unknown
NCT04425135 2020-06-11
Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown
NCT03709953 2018-10-24
Spark-AL003
Guangzhou Institute of Respiratory Disease
Phase 2 Unknown
NCT03411967 2018-01-26
Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC
Zigong No.1 Peoples Hospital
Phase 2 Unknown
NCT03376191 2017-12-18
Apatinib in Advanced Non-squamous，NSCLC
Peking University Cancer Hospital & Institute
Unknown
NCT03135977 2017-12-07
Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT03201146 2017-11-17
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
West China Hospital
Phase 1/2 Unknown
NCT02704767 2016-03-10
Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma
First Affiliated Hospital of Kunming Medical University
Phase 2 Unknown